Construction is expected to begin soon on two separate addition projects at Eli Lilly’s Pleasant Prairie manufacturing facility, located at 10300 128th Ave.
Earlier this month, Indianapolis-based pharmaceutical giant Eli Lilly and Company said it would invest $3 billion to expand the injectables facility it acquired earlier this year from Nexus Pharmaceuticals.
The company has proposed two different initial expansion projects, according to documents submitted to the Pleasant Prairie Plan Commission. The first is a 14,098-square-foot addition to the north of the existing building. The second is a 49,221-square-foot, three-story addition on the west side of the building.
The addition to the west will mainly be used as office space while the addition to the north will be additional warehouse space. Both additions are expected to be completed by March of 2026.
“At the August (Plan Commission) meeting, Lilly indicated that they intended several future expansions at the site,” according to a village staff report.
The expansion in Pleasant Prairie will allow Lilly to bolster its injectable product manufacturing as the company makes medicines to address health issues like obesity and diabetes.
Read more at the BizTimes.